Rapamycin, an mTOR inhibitor, enhances the proliferation and regulates the function of Tregs while decreasing the proliferation of Th1 and Th17 cells in humans and mice with T1D [3,84,85]. Here, MTOR is linked to type 1 diabetes mellitus.